PDF | https://doi.org/10.46613/congastro2023-154
This work is licensed under CC BY 4.0
Puga M1, Sanchez M2, Chilan A2, Conlon C3, Spiazzi R3, Cerezo J3, Omonte A3, Milano C3, Oleas R4, Arevalo M1, Baquerizo J1, Egas M1, Cunto D1, Robles C1, Pitanga H1, Iade B5, Arriola M5, Rainero G6, Meligrana N6, Valero M7, Koll L7, Martinez M7, Simian D8, Maulen C8, Estay C8, García C9, Bellido A10, Ojeda M10, Azañedo C11, Marriott E12, Marriott D12, Andrade D13, Espinoza J13, Vlcek K14, Garcete J14, Martin J15, Faia Y16
1Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Guayaquil, Ecuador
2mdconsgroup, Guayaquil, Ecuador
3Hospital Nacional Profesor Alejandro Posadas (HNPAP), El Palomar, Argentina
4John H. Stroger, Jr. Hospital of Cook County, Chicago, Estados Unidos (EEUU)
5Centro de Asistencia del Sindicato Médico del Uruguay (CASMU), Montevideo, Uruguay
6Hospital Universitario Austral (HUA), Pilar, Argentina
7Instituto de Gastroenterología y Endoscopía de Avanzada (IGEA), Bahía Blanca, Argentina
8Hospital Clínico Universidad de Chile (HCUCH), Santiago, Chile
9, Lima, Perú
10Hospital Cayetano Heredia (HCH), Lima, Perú
11Clinica Internacional, Lima, Perú
12Hospital de Especialidades Teodoro Maldonado Carbo (HTMC),, Guayaquil, Ecuador
13Hospital de Especialidades José Carrasco Arteaga (HJCA), Cuenca, Ecuador
14Hospital Central del Instituto de Previsión Social (HC-IPS), Asunción, Paraguay
15Universidad Católica de Santiago de Guayaquil (UCSG), Guayaquil, Ecuador
16Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, Brasil
BACKGROUND: Damasco is a telemedicine mobile app for Spanish-speaking’s with inflammatory bowel disease (IBD). Its prototype, previously evaluated in a single-centre study, proved to be intuitive and IBD-specific. Some user-patients suggested the participation of healthcare professionals. Damasco is not linked to any hospital. It is free to access. Since June/2023, both Damasco and Damasco-Doctor have been available on iOS and Google Play. Damasco-Doctor is a read-only user for healthcare professionals, to track data from whom follow them.
AIM: To externally validate Damasco through a user-patient acceptance test (UPAT).
METHODS: We contacted IBD users-patients through social media (Facebook/WhatsApp), to assess Damasco and its interaction with Damasco-Doctor. Damasco has been developed in JavaScript, with the following functions: medication reminder, stool characteristics, meals photo-documentation, GPS bathroom finder and e-Learning module. Through a link, the user-patients authorize a Damasco-doctor user to track information. The UPAT was performed using the Mobile Application Rating Score (MARS). A Likert (L) 4-5 (very good-excellent) 80% was the reference.
RESULTS: 53 surveys were retrieved, 40/53 answered ≥70% MARS: median age 34.5 (32-49), 33/40 women; 11/40 foreign surveyed (27.5%); 23/40 public hospitals (57.5%); 22/40 ulcerative colitis (55%), 17/40 Crohn’s disease, 1/40 unclassifiable colitis. There was a higher scoring regarding functionality (L4-5 92.5%), content (89.2%), design (84.2%) and app adherence (66.5%) (Figure 1). Compared to the prototype, there was a significant improvement in the content (76.5%; p<.05) and design (68.7%; p<.05).Damasco was scored with four to five stars by 31/40 (77.5%) and 9/40 (22.5%), respectively. Damasco is a specific IBD app according to 94% of surveyed.
CONCLUSION: Damasco and Damasco-Doctor are high-acceptance tools among IBD Spanish-speaking users-patients. Joint symptoms and a test reminder (colonoscopy, calprotectin) are pending functions. An update must also improve app adherence. This external validation must be completed on a worldwide scale.
